← All trials
NCT00005675
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2000
- Primary completion
- May 1, 2005
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 168
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Lead sponsor
- Medical University of South CarolinaCollaborator
- University of Tennessee, MemphisCollaborator
- University of TennesseeOverall official - principal investigator
- Wayne State UniversityCollaborator
- University of California, Los AngelesCollaborator
- Johns Hopkins UniversityCollaborator
- Georgetown UniversityCollaborator
- Northwestern UniversityCollaborator
- University of Alabama, BirminghamCollaborator
- Department of Veteran AffairsCollaborator
- Icahn School of Medicine at Mount SinaiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.